Momenta Pharmaceuticals (MNTA) was Initiated by Goldman to “Neutral” and the brokerage firm has set the Price Target at $14. Goldman advised their investors in a research report released on Jun 6, 2016.
On the company’s financial health, Momenta Pharmaceuticals reported $-0.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $-0.34. The company had revenue of $19.90 million for the quarter, compared to analysts expectations of $26.74 million. The company’s revenue was up 132.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.
Momenta Pharmaceuticals closed down -0.31 points or -2.54% at $11.89 with 4,75,469 shares getting traded on Friday. Post opening the session at $12.21, the shares hit an intraday low of $11.74 and an intraday high of $12.21 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 23, 2016, Craig A Wheeler (President) sold 5,880 shares at $10.18 per share price. According to the SEC, on May 23, 2016, Bruce Leicher (SVP & General Counsel) sold 1,000 shares at $10.40 per share price. On May 23, 2016, James M. Roach (Senior VP, Development and Chi) sold 1,092 shares at $10.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Momenta Pharmaceuticals Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics Biosimilars and Novel Therapeutics. The Companys product a generic version of Lovenox (enoxaparin sodium injection) was approved by the United States Food and Drug Administration. The Company is developing Complex Generics such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars including M923 and M834. The Company is developing Novel Therapeutics including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923 a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.